These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9215839)

  • 1. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
    Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
    Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
    J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab in peripheral T-cell malignancies.
    Dearden C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
    Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
    J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
    Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
    Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
    Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
    Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
    Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
    Walsh M; Chaudhry A; Jayne D
    Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.
    Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
    Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
    Dyer MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
    Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campath-1H monoclonal antibody therapy.
    Flynn JM; Byrd JC
    Curr Opin Oncol; 2000 Nov; 12(6):574-81. PubMed ID: 11085457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.